Ironwood Pharmaceuticals (IRWD) is a GI specialty pharma whose lead drug, LINZESS (linaclotide), is commercialized 50/50 with AbbVie. The stock trades at $3.68 — down 24% on the week after the CFO resigned the day after the Q1 2026 earnings call. Forward P/E on management's reaffirmed FY guidance is 2.56x. That valuation looks priced for a thesis break that the filing doesn't support, while the moat on the pipeline asset is wider than the tape implies.

What the filing says

Q1 2026 LINZESS U.S. net sales: $272.5M, +97% YoY versus a $138M Q1 2025 trough. Total IRWD revenue $106.5M, GAAP net income $40.8M (swing from -$37.4M loss), Adj. EBITDA $76.7M. Cash $220.5M plus $105.8M AR against the $200M 1.50% convertible maturing June 15 — repayment is cash, not refi. Revolver $550M undrawn, all covenants clean. Year-end debt projected at ≈$300M, under 1× EBITDA.

Management reiterated full-year guidance with "reiterating" language: LINZESS U.S. $1.125-1.175B, Ironwood revenue $450-475M, Adj. EBITDA >$300M. CFO confirmed >$300M as a floor in response to a direct analyst question. The driver is mechanical: Ironwood and AbbVie lowered the LINZESS wholesale list price effective January 1, 2026, which eliminates the IRA inflation-rebate penalty across 2026. The maneuver is durable for the year — not a one-time gross-to-net swing.

Apraglutide (GLP-2 analog for SBS-IF) confirmatory Phase III (STARS-2) initiates Q2 2026: 124 patients, FDA-aligned design, same dose and 24-week endpoint as the positive original STARS. LINZESS pediatric 2-5 sNDA PDUFA is May 24. CFO Greg Martini resigned May 8 — boilerplate "no disagreement" 8-K. Interim is the existing Corporate Controller. No permanent successor named.

What the market thinks

EV ≈$900M (post-convert net debt). At reaffirmed FY EBITDA, 3.0× EV/EBITDA. Backing out our LINZESS franchise PV range ($700M severe MFP / $870M base / $1.05B mild), the current EV is consistent with the market pricing somewhere between base and severe — and assigning zero value to apraglutide.

The stock was $4.83 on May 6 (pre-CFO 8-K) and is $3.68 today. That $1.15/share retrace is almost entirely sentiment from the CFO 8-K — Q1 financials beat, guidance was reaffirmed, and the operational news between May 6 and now is the resignation plus the buildup of activist-exit awareness.

Why the gap exists

Three specific reasons, all verifiable:

1. The "competing trial" referenced on the call is JAGX. Analyst Chase Knickerbocker (Craig-Hallum) asked about a competing SBS-IF trial — the only candidate is Jaguar Health's crofelemer Phase II. Crofelemer is an anti-secretory chloride channel inhibitor, mechanistically distinct from a GLP-2 trophic factor. More importantly, JAGX is at $3.33 from a $241.50 52-week high (-98.6% 1Y), RSI 4.8, forward P/E negative. It cannot finance a Phase III. The "competition" implied on the call is structurally not competition.

2. Takeda is silent on GATTEX. The GATTEX (teduglutide) franchise is the incumbent GLP-2 for SBS-IF, ≈$1B annually. Across eight cached Takeda earnings transcripts, GATTEX has zero narrative discussion — Takeda discusses Entyvio IRA dynamics, oveporexton, rusfertide, zasocitinib, but not the franchise apraglutide is targeting. This matches our pattern playbook's "incumbent narrative silence on disruptor" anti-pattern: the legally required 10-K disclosure is present; the voluntary earnings-call narrative is absent. Asymmetry is the signal.

3. The price reset playbook is peer-validated, not idiosyncratic. BMY's Eliquis ran the identical January 1, 2026 list price reset at four times the scale. BMY Q1 2026: Eliquis $4.1B (+13% YoY), "$1.2 billion lower net cash collections expected to be more than offset later year by lower rebate payments." Same mechanism, same framing language. Validates the LINZESS Q1 print as durable and replicable rather than an accounting artifact. ARWR and IONS executed comparable WAC resets in the same window; CAH (distributor) cites the manufacturer flows.

Risks, ranked

1. 2027 IRA MFP magnitude for LINZESS. Effective January 2027. CMS expected to finalize rules H2 2026. Sector-wide consensus silence (all 10 Round 1 drug owners — BMY, JNJ, MRK, LLY, NVS, AMGN, PFE, NVO, TAK, ABBV/IRWD) declining to quantify. Severe outcome (60%+ Medicare cut) takes equity toward ≈$2.75. Already partially priced as overhang.

2. CFO transition opacity. Day-after-earnings timing is atypical for healthcare CFO transitions — the comparable Q1 2026 healthcare transitions came with named successor and timeline. If the rationale eventually surfaces as strategic disagreement, the discount widens; if it's a benign career move, it reverses.

3. Sarissa (Denner) sold 6.73M shares at $3.05 in March. $20.5M block from a sophisticated activist. Could be "mission accomplished" after the $0.53→$5.78 recovery, or conviction shift. Tier 1 signal weight either way.

4. STARS-2 enrollment risk. 124 patients in a rare disease. Best-case NDA 2028, approval 2029-2030.

5. H2 2026 Medicaid demand softening as states adjust to inflationary-rebate elimination. Factored into guidance, but variance unknown.

Catalysts

What would change our mind

• CMS MFP > 50% Medicare net price cut for LINZESS → recomputes LINZESS PV downward
• CFO rationale surfaces as strategic disagreement (M&A pressure, 2027 disclosure conflict) → governance discount widens
• STARS-2 enrollment lag >6 months past Q3 → apraglutide PV compresses
• Takeda begins narrative defense of GATTEX → moat narrower than thought
• New SBS-IF Phase 2/3 from a properly-capitalized challenger → competitive structure shifts

A permanent CFO announcement before August 31 with credible external hire (45%), STARS-2 dosing before September (78%), and pediatric PDUFA hitting May 24 (85%) would each tighten the upside path. The 2027 MFP magnitude is the single largest variance reducer and the latest meaningful one.

Evidence